| Health / Medical Topics |
Recombinant Vaccinia Viral Vector RO5217790
A vaccine consisting of recombinant modified vaccinia Ankara (MVA) viral vector encoding mutated forms of the genes for the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) type 16 and the human cytokine interleukin-2 (hIL2), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, recombinant vaccinia viral vector RO5217790 may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing HPV E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 have been implicated in the tumorigenesis of cervical carcinoma. (NCI Thesaurus)
YOU MAY ALSO LIKE
A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host…
A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen; MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by…
A drug used to treat high blood levels of uric acid in patients with leukemia, lymphoma, and other types of cancer who…
A recombinant therapeutic agent which is chemically identical to or similar to an endogenous non-mutated melanocyte differentiation antigen expressed by both normal…
A recombinant peptide of the tyrosinase-related protein 1 (TRP1) used in vaccine therapy. Expressed by cells of melanocyte origin, TRP1 is an…
A recombinant agent, which is chemically identical to or similar to the endogenous cytokine tumor necrosis factor-beta (TNF-beta). Produced predominantly by T-lymphocytes…
